{"id":"W1997512486","doi":"10.1136/thoraxjnl-2011-201054c.252","title":"P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial","year":2011,"lang":"en","type":"article","venue":"Thorax","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Minimal clinically important difference; COPD; Muscarinic antagonist; Lama; Placebo; Internal medicine; Inhaler; Dry-powder inhaler; Quality of life (healthcare); Exacerbation; Anesthesia; Randomized controlled trial; Asthma; Antagonist","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000624728,0.0007992869,0.001643736,0.0001866396,0.0002203226,0.0009176369,0.0006443117,0.001226395,0.004395768],"category_scores_gemma":[0.0004446115,0.0002208448,0.001728101,0.0002453503,0.0005232049,0.0003666886,0.000269141,0.001393993,0.0007910444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005160993,"about_ca_system_score_gemma":0.0006422403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001543148,"about_ca_topic_score_gemma":0.004128628,"domain_scores_codex":[0.9997531,0.0001144614,0.00001298639,0.00003825997,0.00002566995,0.00005561173],"domain_scores_gemma":[0.9997502,0.00004367805,0.00005983123,0.00001809743,0.00001571091,0.0001124126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8390042,0.003551144,0.003126364,0.003872322,0.00451267,0.0002640586,0.0001165916,0.000860864,0.01513948,0.000396049,0.008454178,0.1207021],"study_design_scores_gemma":[0.8522482,0.1055708,0.02967956,0.0005312549,0.003057544,0.0004145656,0.0001621938,0.000872109,0.002110561,0.0006464191,0.004625113,0.00008163304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628351,0.03029839,0.0001790226,0.001121431,0.0002981439,0.0005124188,0.00150915,0.0001192137,0.003127113],"genre_scores_gemma":[0.9843103,0.007731348,0.0003234309,0.001576796,0.0003133541,0.0006345763,0.00114357,0.00002009873,0.00394652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004395768,"threshold_uncertainty_score":0.01470524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03614344810495717,"score_gpt":0.301206005092894,"score_spread":0.2650625569879368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}